Angiotensin II-induced growth of vascular smooth muscle cells is associated with modulation of cell surface area and platelet-derived growth factor receptor expression

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 3, 2007, Pages 153-160

  Kuma, Sosei ^a   Oki, Eiji ^a   Onohara, Toshihiro ^a   Komori, Kimihiro ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin; Morphology; Vascular smooth muscle

Indexed keywords

4' [(2 CYCLOPROPYL 7 METHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL][1,1' BIPHENYL] 2 CARBOXYLIC ACID; ANGIOTENSIN II; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL CULTURE; CELL GROWTH; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; FEMALE; GROWTH REGULATION; HUMAN; HUMAN CELL; HYPERPLASIA; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VEIN GRAFT;

ANGIOGENESIS INHIBITORS; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SIZE; CELLS, CULTURED; DOGS; FLOW CYTOMETRY; HINDLIMB; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; REGIONAL BLOOD FLOW;

EID: 33846463382     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04535.x     Document Type: Article

References (53)

1. Angelini GD. Saphenous vein graft failure: Etiologic considerations and strategies for prevention. Curr. Opin. Cardiol. 1992; 7: 939-44.
2. Zubilewicz T, Wronski J, Bourriez A et al. Injury in vascular surgery: The intimal hyperplastic response. Med. Sci. Monit. 2001; 7: 316-24.
3. Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. Rev. Cardiovasc. Med. 2002; 3 (Suppl. 5): S4-9.
4. Azuma H, Niimi Y, Hamasaki H. Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan. Br. J. Pharmacol. 1992; 106: 665-71.
5. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res. 1991; 68: 450-6.
6. Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 2004; 44: 195-202.
7. Powell JS, Clozel JP, Muller RK et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8.
8. Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 1993; 87: 283-90.
9. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J. Clin. Invest. 1994; 93: 339-46.
10. Shiota N, Okunishi H, Fukamizu A et al. Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS Lett. 1993; 323: 239-42.
11. Wang DH, Prewitt RL. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension 1990; 15: 68-77.
12. Wilson DP, Saward L, Zahradka P, Cheung PK. Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc. Res. 1999; 42: 761-72.
13. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989; 13: 305-14.
14. Campbell-Boswell M, Robertson Jr AL. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp. Mol. Pathol. 1981; 35: 265-76.
15. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res. 1988; 62: 749-56.
16. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J. Clin. Invest. 1992; 90: 456-61.
17. 1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur. J. Pharmacol. 1994; 251: 143-50.
18. Makita S, Nakamura M, Yoshida H, Hiramori K. Effect of angiotensin II receptor blocker on angiotensin II stimulated DNA synthesis of cultured human aortic smooth muscle cells. Life Sci. 1995; 56: L383-8.
19. Mii S, Ware JA, Mallette SA, Kent KC. Effect of angiotensin II on human vascular smooth muscle cell growth. J. Surg. Res. 1994; 57: 174-8.
20. Weber H, Taylor DS, Molloy CJ. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J. Clin. Invest. 1994; 93: 788-98.
21. Xiao F, Puddefoot JR, Vinson GP. Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. J. Endocrinol. 2000; 165: 533-6.
22. Touyz RM, Deng LY, He G, Wu XH, Schiffrin EL. Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: Role of extracellular signal-regulated kinases. J. Hypertens. 1999; 17: 907-16.
23. 2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998; 32: 488-95.
24. Morinaga K, Eguchi H, Miyazaki T, Okadome K, Sugimachi K. Development and regression of intimal thickening of arterially transplanted autologous vein grafts in dogs. J. Vasc. Surg. 1987; 5: 719-30.
25. Miyake K, Matsukura M, Yoneda N et al. Discovery and development of aryl-fused imidazole-based angiotensin II antagonists. Bioorg. Med. Chem. Lett. 1994; 4: 213-18.
26. Okunishi H, Song K, Oka Y et al. In vitro pharmacology of a novel non-peptide angiotensin II-receptor antagonist, E4177. Jpn. J. Pharmacol. 1993; 62: 239-44.
27. Inokuchi K, Okadome K, Ohtsuka K et al. A desktop computer to visualize the intraluminal velocity profile and its clinical application. J. Vasc. Surg. 1984; 1: 787-94.
28. Otsuka K, Takahara H, Okadome K, Sugimachi K. Computational simulation method of intraluminal velocity profile proved by laser Doppler velocimeter. J. Surg. Res. 1990; 49: 408-12.
29. Ishida M, Komori K, Yonemitsu Y, Taguchi K, Onohara T, Sugimachi K. Immunohistochemical phenotypic alterations of rabbit autologous vein grafts implanted under arterial circulation with or without poor distal runoff-implications of vein graft remodeling. Atherosclerosis 2001; 154: 345-54.
30. Clowes AW, Clowes MM. Influence of chronic hypertension on injured and uninjured arteries in spontaneously hypertensive rats. Lab. Invest. 1980; 43: 535-41.
31. Powell JS, Muller RK, Rouge M, Kuhn H, Hefti F, Baumgartner HR. The proliferative response to vascular injury is suppressed by angiotensin- converting enzyme inhibition. J. Cardiovasc. Pharmacol. 1990; 16 (Suppl. 4): S42-9.
32. Kohno M, Ohmori K, Nozaki S et al. Effects of valsartan on angiotensin II-induced migration of human coronary artery smooth muscle cells. Hypertens. Res. 2000; 23: 677-81.
33. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253: 1129-32.
34. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 1999; 79: 1283-316.
35. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. 1992; 89: 507-11.
36. Heldin CH, Wasteson A, Westermark B. Interaction of platelet-derived growth factor with its fibroblast receptor. Demonstration of ligand degradation and receptor modulation. J. Biol. Chem. 1982; 257: 4216-21.
37. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ. Res. 1985; 56: 139-45.
38. Davies MG, Kim JH, Klyachkin ML et al. Diabetes mellitus and experimental vein graft structure and function. J. Vasc. Surg. 1994; 19: 1031-43.
39. Jiang Z, Wu L, Miller BL et al. A novel vein graft model: Adaptation to differential flow environments. Am. J. Physiol. Heart Circ. Physiol. 2004; 286: H240-5.
40. Landymore RW, Kinley CE, Cameron CA. Intimal hyperplasia in autogenous vein grafts used for arterial bypass: A canine model. Cardiovasc. Res. 1985; 19: 589-92.
41. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, Steinberg MI. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci. 1991; 49: PL223-8.
42. Kawamura M, Terashita Z, Okuda H et al. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J. Pharmacol. Exp. Ther. 1993; 266: 1664-9.
43. Kino H, Hama J, Takenaka T et al. Effect of an angiotensin II receptor antagonist, TCV-116, on rat carotid artery neointimal formation after balloon injury. Blood Pressure 1994; 5: 43-8.
44. Yuda A, Takai S, Jin D et al. Angiotensin II receptor antagonist, L-158,809, prevents intimal hyperplasia in dog grafted veins. Life Sci. 2000; 68: 41-8.
45. Assender JW, Irenius E, Fredholm BB. 5-Hydroxytryptamine, angiotensin and bradykinin transiently increase intracellular calcium concentrations and PKC-alpha activity, but do not induce mitogenesis in human vascular smooth muscle cells. Acta Physiol. Scand. 1997; 160: 207-17.
46. Abe J, Deguchi J, Matsumoto T et al. Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: A link between angiotensin II and intimal thickening. Circulation 1997; 96: 1906-13.
47. Carini DJ, Duncia JV, Aldrich PE et al. Nonpeptide angiotensin II receptor antagonists: The discovery of a series of N-(biphenylylmethyl) imidazoles as potent, orally active antihypertensives. J. Med. Chem. 1991; 34: 2525-47.
48. Mizuno K, Niimura S, Tani M et al. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats. Life Sci. 1992; 51: PL183-7.
49. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: The VALPREST trial. J. Invasive Cardiol. 2001; 13: 93-7.
50. Yoshida O, Hirayama H, Nanasato M, Watanabe T, Murohara T. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: A prospective randomized study under intravascular ultrasound guidance. Am. Heart J. 2005; 149: e2.
51. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: Humans versus rodents. Jpn. J. Pharmacol. 1993; 62: 207-10.
52. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992; 86: 100-10.
53. Ribichini F, Wijns W, Ferrero V et al. Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting. Am. J. Cardiol. 2003; 91: 154-8.